Liposomal Bupivacaine Versus Bupivacaine Hydrochloride with Lidocaine during Midurethral Sling Placement: A Randomized Controlled Trial

被引:14
|
作者
Iwanoff, Christopher [1 ,2 ]
Salamon, Charbel [1 ]
机构
[1] Atlantic Hlth Syst, Div Female Pelv Med & Reconstruct Surg, Morristown, NJ USA
[2] Madigan Army Med Ctr, Div Female Pelv Med & Reconstruct Surg, Joint Base Lewis Mcchord, WA USA
关键词
Liposomal bupivacaine; Exparel; Midurethral sling; Postoperative pain; VISUAL ANALOG SCALE; URINARY-INCONTINENCE; SURGICAL-PROCEDURE; STRESS;
D O I
10.1016/j.jmig.2018.11.005
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Study Objective: To study the effects of liposomal bupivacaine (LB) compared with bupivacaine hydrochloride with lidocaine on postoperative day 1 pain scores. Design: A randomized controlled trial (Canadian Task Force classification 1). Setting: An academic medical center within the department of female pelvic medicine and reconstructive surgery. Patients: Fifty-seven patients undergoing midurethral sling placement by a fellowship-trained urogynecologic surgeon and a fellow in female pelvic medicine and reconstructive surgery. Interventions: Fifty-seven patients were enrolled to participate in this study. There were 24 patients randomized to receive liposomal bupivacaine and 33 to receive a mixture of bupivacaine and lidocaine during the placement of a retropubic midurethral sling. Measurements and Main Results: Patients were given a diary of pain scales and asked to record their level of pain using the provided visual analog scale scored on a 100-mm Likert scale. Patients recorded their pain 4 hours after hospital discharge and on the night of surgery and their most intense pain each day thereafter for 7 days postoperatively. In addition, patients recorded total opioid and nonsteroidal anti-inflammatory drug consumption daily for 1 week postoperatively. Finally, the quality of recovery was assessed using the Quality of Recovery-15 (QoR-15) questionnaire scores. The median pain score in the experimental group was 20 mm (range, 0-80 mm) versus 30 mm (range, 0-60 mm) in the comparative group (p = .046). The postoperative day 1 QoR-15 scores were significantly lower in the LB group (124 [range, 54-150] vs 144 [range, 68-150], p = .007). There were no significant differences in opioid and nonsteroidal anti-inflammatory drug consumption, the remaining pain scores, or postoperative day 7 QoR-15 scores. Conclusion: The results suggest the use of liposomal bupivacaine during retropubic midurethral sling placement does not provide a clinically significant difference in postoperative day 1 pain scores when compared with immediate-acting bupivacaine hydrochloride and lidocaine. (C) 2019 Published by Elsevier Inc. on behalf of AAGL.
引用
收藏
页码:1133 / 1138
页数:6
相关论文
共 50 条
  • [41] Femoral Nerve Block Versus Liposomal Bupivacaine Infiltration For Total Knee Arthroplasty Postoperative Pain: A Randomized Controlled Trial
    Toor, Jaspreet
    Dowling, Oonagh
    Scuderi, Giles
    Marino, Joseph
    Overdyk, Frank
    Farquhar, Rena
    Gencorelli, Susan
    ANESTHESIA AND ANALGESIA, 2017, 124 : 1061 - 1062
  • [42] Interscalene Brachial Plexus Block with Liposomal Bupivacaine versus Standard Bupivacaine with Perineural Dexamethasone: A Noninferiority Trial
    Kim, David H.
    Liu, Jiabin
    Beathe, Jonathan C.
    Lin, Yi
    Wetmore, Douglas S.
    Kim, Sang J.
    Haskins, Stephen C.
    Garvin, Sean
    Oxendine, Joseph A.
    Ho, Michael C.
    Allen, Answorth A.
    Popovic, Marko
    Gbaje, Ejiro
    Wu, Christopher L.
    Memtsoudis, Stavros G.
    ANESTHESIOLOGY, 2022, 136 (03) : 434 - 447
  • [43] Reply: The Analgesic Effects of Liposomal Bupivacaine versus Bupivacaine Hydrochloride Administered as a Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction: A Prospective, Single-Blind, Randomized, Controlled Trial
    Ha, Austin Y.
    Guffey, Ryan
    Myckatyn, Terence M.
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2020, 145 (05) : E998 - E999
  • [44] Liposomal bupivacaine reduces opiate consumption after rotator cuff repair in a randomized controlled trial
    Sethi, Paul M.
    Brameier, Devon T.
    Mandava, Nikhil K.
    Miller, Seth R.
    JOURNAL OF SHOULDER AND ELBOW SURGERY, 2019, 28 (05) : 819 - 827
  • [45] Liposomal Bupivacaine Block at the Time of Cesarean Delivery to Decrease Postoperative Pain A Randomized Controlled Trial
    Prabhu, Malavika
    Clapp, Mark A.
    McQuaid-Hanson, Emily
    Ona, Samsiya
    O'Donnell, Taylor
    James, Kaitlyn
    Bateman, Brian T.
    Wylie, Blair J.
    Barth, William H., Jr.
    OBSTETRICS AND GYNECOLOGY, 2018, 132 (01): : 70 - 78
  • [46] Comparing bupivacaine alone to liposomal bupivacaine plus bupivacaine in interscalene blocks for total shoulder arthroplasty: a randomized, non-inferiority trial
    Elmer, Donald A.
    Coleman, John R.
    Renwick, Christian M.
    Amato, Peter E.
    Werner, Brian C.
    Brockmeier, Stephen F.
    Slee, April E.
    Hanson, Neil A.
    REGIONAL ANESTHESIA AND PAIN MEDICINE, 2023, 48 (01) : 1 - 6
  • [47] Dexamethasone Plus Bupivacaine Versus Bupivacaine in Bilateral Transincisional Paravertebral Block in Lumbar Spine Surgeries A Randomized Controlled Trial
    Alansary, Amin M.
    Aziz, Mohamed M.
    Elbeialy, Marwa A. K.
    CLINICAL JOURNAL OF PAIN, 2023, 39 (09): : 458 - 466
  • [48] Intrathecal levobupivacaine versus bupivacaine for inguinal hernia surgery: a randomized controlled trial
    Singh, Ajay
    Gupta, Anshu
    Datta, Priyankar Kumar
    Pandey, Maitree
    KOREAN JOURNAL OF ANESTHESIOLOGY, 2018, 71 (03) : 220 - 225
  • [49] RANDOMIZED CLINICAL TRIAL OF LIDOCAINE VS. BUPIVACAINE FOR PARACERVICAL BLOCK DURING LAMINARIA PLACEMENT IN SECOND-TRIMESTER ABORTION
    Davison, J.
    Murthy, A.
    Webb, A.
    CONTRACEPTION, 2012, 86 (02) : 176 - 177
  • [50] 0.25% bupivacaine-1% lidocaine vs 0.5% bupivacaine for ultrasound-guided infraclavicular brachial plexus block: a randomized controlled trial
    Aguilera, German
    Tabilo, Camilo
    Jara, Alvaro
    Aliste, Julian
    REGIONAL ANESTHESIA AND PAIN MEDICINE, 2024,